Print E-mail Contact us
Anti-viral Program
A series of in vitro assays are available for HIV, HCV, HBV, Influenza virus, RSV, and Flaviviruses such as Dengue virus that are prevalent in many regions. The assays are HTS
compatible and immediately available to support your Hit ID and Lead discovery efforts.
Anti-HCV Assay and Screening
HCV replicon assay aiming GT1a, 1b or 2a is available in both 96-well and 384-well format. The system base on JFH-1, with or without reporter gene, is for compound screening to capture full cycle of viral replication. For other genotypes, HDB provides services for customized construction of chimeric virus according to client's request, and the screening
supports against the customized chimeric replicons.
The services also include:
-
Evaluation of effect of drug combination against HCV
-
Entry studies of inhibitors using pseudovirus infection system
-
Generation of mutated HCV replicons by site-directed mutagenesis
-
Genotyping and phenotyping for viruses derived from HCV-infected patients or drug-resistant virus generated for study purpose
-
RNA polymerase assay established against HCV NS5b polymerase in HTS format that can be used to determined the compound activity against HCV NS5b polymerase
-
Assay development for chimeric replicons and mechanism of action of lead compounds
Anti-RSV Assay and Screening
HDB offers anti-RSV CPE assay and cytotoxicity assay in 96/384 formats. The assays are HTS compatible, and have been extensively used in compound screening. A secondary
assay, fussion reporter gene assay, is also available for compound tests.
The services also include:
-
Compound profiling against different serotypes
-
Assay development for mechanism of action of lead compounds
Anti-HBV Assay and Screening
A 96-well qPCR assay is available in HDB for determining the compound inhibition of HBV
in HepG2.2.2.15 cell line.
We also provide:
-
Compound profiling against clinical mutant HBVs
-
Assay development for HBV entry blockers
-
Assay development for mechanism of action of lead compounds
-
Cytotoxicity evaluation of the tested compounds
Anti-Influenza Virus Assay and Screening
A CPE based 96-well/384-well assay is available at HDB for testing the compound
inhibition of influenza virus A/B in MDCK cells.
We also provide:
-
Compound profiling against different influenza virus strains
-
Assay development for mechanism of action of lead compounds
-
Cytotoxicity evaluation of the tested compounds
----------------------
----------------------
HD Biosciences (China) Co.,Ltd
590 Ruiqing Road
Zhangjiang East Campus, Pudong, Shanghai 201201,
P.R.China
Tel: +86 (21) 5116 3700
Fax: +86 (21) 5116 3766
info@hdbiosciences.com
SERVICES
|
THERAPEUTIC AREAS
|
NEWS & EVENTS